WuXi Biologics (Cayman) Inc. has announced a strategic collaboration with Virogen Biotechnology Inc. to advance the development and commercialization of VG712, Virogen's lead clinical-stage asset. Under this partnership, WuXi Biologics will provide comprehensive services, including technology transfer, process validation, and commercial manufacturing for both the drug substance and drug product of VG712. This collaboration aims to accelerate VG712's path to global market approval. VG712, a first-in-class anti-CD3 immunotoxin, is designed to restore immune function by depleting the patient's existing T cell pool, a strategy known as immunological reset. The drug has received Fast Track designation from the U.S. Food and Drug Administration, and a pivotal Phase II trial is currently underway. A Biologics License Application submission is anticipated between 2027 and 2028. No results from this trial have been presented yet.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.